Justyna Kelly - Dec 1, 2021 Form 3 Insider Report for POINT Biopharma Global Inc. (PNT)

Role
Chief Operating Officer
Signature
/s/ William L. Demers, by Power of Attorney for Justyna Kelly
Stock symbol
PNT
Transactions as of
Dec 1, 2021
Transactions value $
$0
Form type
3
Date filed
12/10/2021, 10:27 AM
Next filing
Dec 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PNT Stock Option (Right to Buy) Dec 1, 2021 Common Stock 26.9K $6.97 Direct F1, F2
holding PNT Stock Option (Right to Buy) Dec 1, 2021 Common Stock 4.93K $8.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 30, 2021, POINT Biopharma Global Inc. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer, merged with and into POINT Biopharma Inc. ("Old POINT"). At the effective time of the Business Combination, each option to acquire shares of Old POINT was exchanged for an option to acquire shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported options to acquire the Issuer's Common Stock in consideration for the options to acquire equity securities of Old POINT held by the Reporting Person prior to the Business Combination.
F2 The option vested 25% on November 3, 2021 with the remaining 75% vesting in three equal annual installments thereafter.
F3 The option vests 25% on July 6, 2022 with the remaining 75% vesting in three equal annual installments thereafter.

Remarks:

Power of Attorney is attached to this Form 3 as Exhibit 24